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Abstract 
 
Studies of widely diverse species of a protein are a powerful tool to gain 
information on the structure and function of the protein.  We investigated the 
response of human, pig, shark and killifish cystic fibrosis trans-membrane 
conductance regulator (CFTR) to specific inhibitors of the channel: CFTRinh-
172, GlyH-101, and glibenclamide.  In several expression systems, including 
isolated perfusions of the rectal gland, primary cell cultures of rectal gland tubules 
and oocyte expression, we observed fundamental differences in the sensitivity to 
inhibition by these CFTR blockers.  We used primarily two-electrode voltage 
clamping of cRNA microinjected Xenopus laevis oocytes.  In oocyte studies, 
shark CFTR was insensitive to CFTRinh-172 (maximum inhibition 8 ± 1.4% at 
20µM), pCFTR was insensitive to Glibenclamide (maximum inhibition 12.8 ± 
4.2% at 200µM), and all species were sensitive to GlyH-101 (maximum inhibition 
with pCFTR of 80.2 ± 3.6% at 20µM). Shark CFTR was completely insensitive to 
inhibition by CFTRinh-172 in short circuit current experiments  (2.5 ± 0.15 % 
inhibition of chloride secretion) compared to inhibition with GlyH-101 (56.5 ± 
6.56 % inhibition of chloride secretion). Perfusion studies confirmed these results. 
These experiments demonstrate a profound difference in the sensitivity of 
different CFTR species to inhibition by CFTR blockers. However, the amino acid 
residues that have been proposed by site directed mutagenesis studies to be 
responsible for inhibitor binding are uniformly conserved in all four isoforms 
studied. Therefore, the differences cannot be explained by simply targeting one 
amino acid for site-directed mutagenesis.  Rather, the potency of the inhibitory 
actions of CFTRinh-172, Gly-H101 and glibenclamide on the CFTR molecule is 
dictated by the local environment and the three dimensional structure of residues 
that form the vestibule and the chloride pore. 
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Introduction 
Overview of Cystic Fibrosis 
Cystic fibrosis (CF) is a prototypical example of a simple mutation in a 
single gene that ultimately causes a complex disease. (1-2) CF is caused by 
mutations in the cystic fibrosis trans-membrane conductance regulator (CFTR) 
protein, a chloride channel and regulatory protein found in exocrine glandular 
tissues. As a result, CF is a disorder of exocrine function involving multiple organ 
systems. The autosomal recessive disorder is the most common lethal inherited 
disease in the Caucasian population and affects more than 1 in 3000 live births. 
(3)  The current median age of survival is 36.9 years of age, with affected males 
typically living longer than affected females. (3) Diagnosis of CF is made by 
evidence of clinical manifestations of CF in at least one organ system and 
evidence of abnormal chloride secretion: an elevated sweat chloride (>60 
mmol/L) on two occasions, presence of two disease causing mutations or an 
abnormal nasal potential difference.  While there are over 1,400 mutations in the 
CFTR gene reported to cause CF, the most common mutation, F508 is a deletion 
of the three nucleotides encoding phenylalanine at position 508.  This mutation 
accounts for over two thirds of CF cases worldwide and 90% of the cases in the 
United States. (4)  
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CF is caused by defective CFTR mediated chloride transport which causes 
increased sodium and water absorption across epithelial cells and results in thick 
viscous secretions in the pancreas, lung, liver, intestine, reproductive tract and 
dermis. (5) Clinical manifestations of CF are recurrent respiratory infections, 
pancreatic enzyme insufficiency, and elevated sweat chloride levels. Respiratory 
manifestations occur in nearly 90% of homozygous patients who survive infancy. 
Increased airways secretions caused by defective chloride secretion causes 
decreased muco-cilliary function and defective clearance of the airways.  As a 
result, CF patients become colonized at an early age with pathogenic bacteria, 
often Staphylococcus aureus and Pseudomonas aeruginosa. Patients develop a 
persistent chronic cough, hyperinflation of the lungs, and pulmonary function 
tests demonstrate obstructive airway disease.   As the disease progresses, chronic 
bronchitis is accompanied by malaise, anorexia, weight loss and digital clubbing.   
Typically, CF patients ultimately succumb to complications related to their 
pulmonary disease. (5-6) 
Due to the multi-system clinical manifestations of the disease, treatment 
regimes for CF patients typically involve a team of specialists including 
pulmonary, endocrine and nutritional specialists.  The primary goal of CF 
treatment includes maintaining lung function, controlling respiratory infections, 
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clearing mucus from the airways and administering nutritional therapy to offset 
pancreatic insufficiency.  Acute pulmonary exacerbations are often treated at 
home but frequently require hospitalization.   Current therapies include, chest 
physical therapy, postural drainage, inhaled bronchodilator treatment, 
administration of Dornase alfa and inhaled and intravenous antibiotics. (6-7) Gene 
therapy, correction of abnormal protein folding, improvement of endogenous ion 
channel function and induction of alternate channels are some of novel 
therapeutic strategies for CF that are being explored with variable success in 
clinical trials. (6-7) 
Cystic Fibrosis Transmembrane Conductance Regulator 
CFTR is a phosphorylation dependent epithelial chloride channel located 
in the apical membrane of epithelial cells in the lungs, liver, pancreas, digestive 
tract, reproductive tract and skin. (5-9) The identification of the primary sequence 
of CFTR was made in 1989 and CFTR was classified as a part of the ATP binding 
cassette (ABC) transporters, traffic ATPases that use the energy from ATP 
hydrolysis for transport. (13-14) The complete structure of the CFTR protein has 
not yet been experimentally determined by X-ray crystallography largely because 
the significantly hydrophobic trans-membrane regions are difficult to crystallize. 
Currently only low-resolution structures of the several domains of the protein 
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Ion permeation is influenced by the presence of charged amino acid side 
chains at the entrance of the channel pore (16). These specific residues attract 
oppositely charged ions, which increase the effective local concentration, while 
also repelling ions of similar charge. Site directed mutagenesis studies have been 
used to identify the role of positive charged residues in ion conductance (17-18). 
Functional evidence suggests that permeant anions bind to several discrete sites 
within the CFTR channel pore (19-24). These binding sites may be involved in 
attracting chloride ions into the CFTR pore (21) and in coordinating ion-ion 
interactions that are necessary for rapid ion movement through the pore (24-26).  
 Specific inhibitors of the CFTR channel have been employed as tools to 
investigate further the role of key amino acids in the channel pore.  Chloride ion 
binding sites within the pore may also be binding sites for small molecules that 
occlude the pore and thus inhibit chloride transport. (25, 30-31) Several organic 
anions have been demonstrated to occlude and inhibit chloride transport, 
including glibenclamide, a sulfonourea (31, 34-35), CFTRinh-172 a thiazolidone 
(36-39), and GlyH-101, a glycine hydrazide (40).  Glibenclamide and GlyH-101 
are thought to act as open channel blockers: glibenclamide acting from the 
internal membrane surface and GlyH-101 from the external surface. CFTRinh-
172 is thought to bind at the R domain and does not act as an open channel 
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blocker. (37) Initial studies suggest that CFTRinh-172 acts optimally during the 
open state of the channel. (36-39) However, despite numerous site-specific 
mutagenesis studies, the location and number of those inhibitor binding sides 
remain unclear (30, 43-46).  
An important limitation of site directed mutagenesis studies is that 
manipulation of the amino acid sequence may cause disruption of important 
secondary or tertiary structural relationships thus causing inaccurate conclusions 
regarding changes in protein function observed or relative importance of mutated 
amino acids.  Cross species comparison studies serve as a powerful method to 
analyze structure and function relationships (41-42, 47-48).  The evolutionary 
differences in amino acid sequences that arise over time and the conservation of 
specific motifs in different species help to define the functional significance of 
specific amino acids without the limitations of site directed mutagenesis.  
Statement of Purpose 
Several years ago, members of our lab observed profound differences in 
the response of shark and human CFTR in response to three thiol-reactive 
substances: mercury, zinc and glutathione. Site-specific mutations introduced at 
shark unique cysteines in human CFTR revealed restoration of sensitivity to 
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mercury mediated inhibition only observed in shark. (41-42) At this time, our lab 
also observed that the novel CFTR specific inhibitor, CFTRinh-172, did not 
inhibit CFTR mediated chloride secretion in short circuit current studies of shark 
rectal gland tissues monolayers and in perfusion studies of the intact shark rectal 
gland.  These preliminary experiments prompted me, several years ago, to explore 
the apparent species differences between shark and human CFTR in response to 
CFTRinh-172 using two-electrode voltage clamping of Xenopus laevis oocytes. I 
discovered that shark indeed was not sensitive to the significant inhibition of 
conductance seen in the human ortholog of CFTR. (49) Realizing that CFTRinh-
172, glibenclamide and GlyH-101 may all inhibit chloride permeation through 
interactions with the pore, my work has been expanded to study the inhibition of 
all three CFTR specific inhibitors on four species of CFTR: shark, human, pig and 
killifish.  The purpose of this work was to explore the pharmacologic profiles of 
these CFTR specific inhibitors across several species to elaborate structural and 
functional relationships. 
Materials and Methods 
This student participated in the shark rectal gland perfusion studies, the 
measurement of short circuit current, the synthesis of human and shark CFTR 
cRNA, the harvesting and injection of Xenopus laevis oocytes, and initial studies 
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of CFTR specific inhibitor, CFTRinh-172, on shark and human CFTR.    Other 
colleagues in the lab, specifically Klaus and Max Stahl carried out additional 
studies in pig and killifish CFTR with the multiple inhibitors. 
In vitro perfusion of shark rectal glands. 
Rectal glands were obtained from either sex of dogfish sharks, Squalus 
acanthias, weighing 2-6 kg.  Glands were removed and cannulae were placed in 
the single artery, vein and duct as described previously (33).  Glands were placed 
in a glass perfusion chamber at 15°C equilibrated with running seawater.  Glands 
were perfused with an elasmobranch Ringer's solution (270mM NaCl, 4mM KCl, 
3mM MgCI2, 2.5 mM CaCi2, 1 mM KH2PO4, 8mM NaHCO3, 350mM urea, 
5mM glucose, and 0.5 mM Na2SO4) (all from Sigma Chemical Co., St. Louis, 
MO) and equilibrated to pH 7.5 by bubbling with 99% 02 and 1% CO2. The 
glands were perfused with shark Ringers solution for thirty minutes to reach basal 
levels of chloride secretion (250µEq/h/g).  Forskolin and IBMX were added to 
the solution at 1µM and 100µM respectively.  Chloride secretion was measured in 
1-min intervals. After twenty minutes of stimulated secretion, 10µM CFTRinh-
172 was added to the perfusion solution for thirty additional minutes (50-80min) 
and then removed.  Measurements of duct flow were made at 10-min intervals in 
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all experiments. Results are expressed as micro equivalents of chloride secreted 
per hour per gram wet weight (μEq/h/g)p ±SEM.  
Primary Cell Cultures of Shark Rectal Gland Tubules. 
Primary cultures of shark rectal gland epithelial cell monolayers were 
prepared per a protocol previously described (43).  Rectal glands were excised 
under sterile conditions, sliced horizontally into 2-3 mm sections, and minced into 
a slurry with two sterile scalpel blades.  The mince was transferred into a 50 ml 
conical tube and washed 3x with 20 ml of sterile shark Ringer’s.  The mince was 
suspended in a collagenase solution (0.2% in 30 ml of sterile shark Ringer’s) and 
incubated at 25˚C for 1 hour under constant agitation.  At the end of the 
incubation, the suspension was washed with sterile shark Ringer’s by 
centrifugation at 200xg at 4˚C for 45 seconds.  The supernatant was discarded and 
the pellet was re-suspended in 20 ml of sterile shark Ringer’s.  The digested 
mince was agitated to release the tubules into the supernatant.  The suspended 
tubules were harvested and kept on ice.  Suspension, agitation, and harvesting of 
the tubules were repeated two more times.  The tubules were next washed and 
suspended in 20 ml of sterile shark Ringer’s, from which two 1 ml aliquots were 
removed to determine the total yield by wet weight.  Average yields were 250-500 
mg wet wt/gland.  The tubules were then suspended in a medium composed of 
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Dulbecco's Modified Eagle's Medium/Ham's F-12 (15 mM HEPES, 3.9 mM 
CaCl2, 2.5 mM MgCl2, 300 mM urea, 94 mM NaCl, 150 mM trimethylamine 
oxide, 21 mM NaHCO3, 10 ml/l penicillin/streptomycin (10000 U x 10 mg-1 x ml-
1), 10 ml/l ITS+, and 50 ml/l Nu-Serum).  Tubules, at a density of ~10 mg/ml, 
were seeded onto 1.2 ml rat tail collagen gels (Cohesion Technologies) in 35 mm 
dishes supported with 150 µm nylon mesh.  The tubules were allowed to grow to 
confluence at 18°C under 95% O2 and 5% CO2, typically within 10-14 days.  The 
nylon mesh containing the monolayer of cells was excised from the petri dish 
using a sterile scalpel blade and mounted in an Ussing chamber.  Both the apical 
and basolateral sides of the monolayer were bathed with shark Ringer’s 
containing 5 mM glucose at pH 7.5. 
 
Measurements of Transepithelial Chloride Transport as Short Circuit Current 
(Isc) in Primary Culture Monolayers: inhibition with CFTRinh-172 and GlyH101 
Confluent cultures were mounted in a conventional Plexiglas Ussing 
chamber with an aperture of 0.28 cm2.  Both hemi-chambers were independently 
perfused by gravity flow at room temp (20-22˚C) with shark Ringer’s solution and 
95% O2 - 5% CO2.  Trans-epithelial voltages were measured with an Iowa dual 
voltage clamp (model 710C) and agar bridges connected to calomel electrodes 
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using methods previously described (43-44).  The bridges were filled with shark 
Ringer solution and were positioned approximately 1 mm from the apical and 
basolateral surfaces of culture.  Trans-epithelial resistance was measured by 
applying bipolar current pulses every 50 seconds.  The voltage clamp 
administered current via agar bridges linked to external Ag-AgCl electrodes.  
Short circuit current (Isc), or net electrogenic chloride secretion (43), was 
measured by determining the current necessary to clamp the spontaneous trans-
epithelial voltage to 0 mV.  Inhibition by CFTRinh-172 and GlyH101 was 
determined by the ratio of Isc measured at the peak of stimulation (1µM 
Forskolin) and Isc at the highest concentration of the inhibitors. Results are 
expressed as microampere per cm2 (µA/cm2) ± SE. 
To study GlyH-101, the organic compound was added after steady state 
conditions were reached at concentrations of 30, 60, 90 and 120µM to the 
mucosal side of the monolayers.   The study of CFTRinh-172 was similar to that 
of GlyH-101.   
Synthesis of hCFTR, pCFTR, kfCFTR, and sCFTR cRNA:  
All CFTR orthologues were cloned into T7 expression vectors. Human, 
shark and pig CFTR sequences were in pcDNA3.1, whereas kfCFTR was in 
pGEMTeasy expression vector.  The vectors were grown up in 150ml cultures of 
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TOP10 electrically competent E. coli (Invitrogen, Crlsbad, CA) and subsequently 
isolated using Pure Yield Maxiprep Systems (Promega, Madison, Wisconsin).  
The clones were whole length sequenced to confirm the integrity of the CFTR 
ORFs. 12µg CFTR DNA was linearized with XhoI and purified by PCR 
purification (Qiagen, Alameda, CA). Capped cDNA was synthesized using T7 
RNA polymerase and in vitro transcription following the instructions of T7 in 
vitro transcription system (Ambion, Austin, TX). The reaction products were 
precipitated using lithium-chloride precipitation and tested with the Agilent 
Bioanalyzer system (Agilent, Santa Clara, CA). (50) 
Oocyte preparation and expression of hCFTR, pCFTR, kfCFTR and sCFTR. 
Mature female Xenopus laevis (Xenopus I, Dexter, Michigan) were 
anesthesized in a 0.15 % cold solution of tricaine for 20min, and several ovarian 
lobules were removed under sterile conditions through an abdominal incision per 
the protocol approved by the Yale University Institutional Animal Care and Use 
Committee. The ovarian lobules were manually dissected in smaller pieces and 
kept in calcium free ND96 (96mM NaCl, 1mM KCl, 1mM MgCI2·6H2O, 5mM 
HEPES (1/2 Na) equilibrated to pH 7.5) (all from Sigma Chemical Co., St. Louis, 
MO). Oocytes were de-folliculated by incubating in a 2.5mg/ml solution of type I 
collagenase for 2 hours and subsequently treating with a hypertonic potassium 
  16
phosphate solution. Mature stage V and VI oocytes were selected and stored in 
modified Barth solution (MBS) (88mM NaCl, 1mM KCl, 2.4mM NaHCO3, 
0.82mM MgSO4·7H2O, 0.33mM Ca(NO3)·4H2O, 0.41mM CaCl2·H2O, 10mM 
HEPES (1/2 Na) and 1% Penicillin/Streptomycin equilibrated to pH 7.4) (all from 
Sigma Chemical Co., St. Louis, MO) at 18°C.  The oocytes were injected with 1-
5ng of cRNA / 50nl or an equivalent volume of water and stored for 1-2 days in 
MBS at 18°C. (50) 
Two electrode voltage clamping: inhibition of hCFTR, pCFTR, kfCFTR and 
sCFTR with CFTRinh-172, GlyH101, and Glibenclamide. 
Electrophysiological recordings were performed 1-2 days after injection of 
the cRNA. Electrodes were pulled on a micropipette puller (Sutter Instruments, 
Novata, CA), the electrodes were filled with 3M KCl and had input resistances 
between 0.6 and 1.3 MΩ.   During two-electrode voltage clamping recording, 
current-voltage (I-V) curves were obtained by clamping the voltage over a ramp 
from -120 to +60 mV at a rate of 100mv/s with the use of a two-electrode voltage 
clamp (TEV-200, Dagan Instruments, Foster City, CA). After correcting for 
capacity currents, reversal potentials were determined and conductances were 
calculated over a range of ±20mV.  During the experiment, the oocytes were 
perfused with calcium containing ND96 (ND96 in addition of 1.8mM 
CaCl2·H2O). I-V ramps were taken under basal conditions and during stimulation 
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by forskolin (10µM) and IBMX (1mM). Once the stimulation reached a steady 
state, the different inhibitors were added beginning with the smallest inhibitor 
concentration. Once currents with one concentration of the specific inhibitor 
reached a steady state, the next higher concentration of the same inhibitor was 
used. IBMX and Forskolin were used continuously throughout stimulation and 
inhibition.  Washout was performed with ND96 alone.  The inhibitors used were 
CFTRinh-172 (Sigma, Cystic fibrosis therapeuticals), GlyH-101 (Cystic fibrosis 
therapeuticals) and Glibenclamide (Sigma) at concentrations of 5, 10 and 20 µM. 
The maximum dose of 20µM was used for two reasons: first at greater 
concentrations of drug used, solubility became a factor and secondly, 20 µM was 
near maximum inhibition demonstrated in all species. In all experiments 
inhibition was determined by the ratio of the conductance measured at steady state 
conductance of IBMX and Forskolin mediated stimulation and the conductance 
obtained at the steady state of inhibition by the specific dose of the specific 
inhibitor.  Data was analyzed with pCLAMP software.  Results are expressed as 
micro Siemens (µS) ± SE.  
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glibenclamide, and GlyH-101 were then added and the mean % inhibition was calculated (n=4-6 
per group).  
Glibenclamide:  Chloride secretion 
 Individual experiments demonstrate a modest inhibition of chloride 
secretion by glibenclamide when compated to gly-H inhibition. (15.8 +/- 16.5 % 
inhibition of Isc) 
CFTRinh-172:  Chloride secretion. 
 Individual experiments demonstrate activation of Isc from basal values 
after the addition of 10µM Forskolin and 1µM VIP.  Steady state stimulation 
occurs after 40 min with Isc currents typically greater than 80 µA.   The addition 
of GlyH-101 to this activating cocktail again causes a similar decrease in current 
to values below 60µA as was demonstrated in the previously described 
experiments.  However, the addition of 50µM CFTRinh-172  to the perfusate does 
not cause a further decrease in short circuit current but rather the current is 
observed to remain at the steady state currents observed after the addition of 
GlyH-101. Figure 2 demonstrates the percent inhibition in shark CFTR 
mediated chloride secretion by GlyH-101 (n=4) and CFTRinh-172 (n=3). 
CFTRinh-172, in contrast to GlyH-101, does not inhibit sCFTR secretion short 
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circuit current (CFTRinh-172; 2.5 ± 0.15 % inhibition, GlyH-101; 56.5 ± 6.55749 
% inhibition). 
Conductance of hCFTR, kfCFTR, pCFTR, sCFTR and un-injected and water 
injected controls under basal and stimulated conditions.  
The conductance of oocytes was measured 2-3 days post injection in 109 
oocytes injected with hCFTR (n=20), kfCFTR (n=25), pCFTR (n=21), sCFTR 
(n=15), water (n=12) and un-injected (n=12).  Human CFTR, kfCFTR, pCFTR 
and sCFTR had basal conductances of 11.9 ± 1.4 µS, 20.5 ± 1.9 µS, 13 ± 3.3 µS 
and 6.7 ± 1.3 µS respectively. Un-injected and water injected control oocytes had 
a significantly lower baseline conductance of 7.2 ± 1.2 µS and 6.2 ± 0.6 µS, 
respectively (P  0.05) compared with baseline conductances of hCFTR, kfCFTR, 
pCFTR and sCFTR.  
Because the aim of the study was to study the effects of CFTR specific 
inhibitors after activation of CFTR, it was important to establish comparable 
steady state conductances amongst the four species of CFTR.  After the addition 
of 10µM forskolin and 1mM IBMX to the perfusate, hCFTR, kfCFTR, pCFTR 
and sCFTR had similar steady state conductances (206 ± 21.9 µS, 218.7 ± 14.3, 
160.1 ± 29.5 µS and 160.7 ± 34 µS). While the steady state activated 
conductances of hCFTR and kfCFTR appeared larger than those of pCFTR and 
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The conductance changes over time are demonstrated in representative 
experiments in Figure 4.  In all species of CFTR, stimulation with forskolin and 
IBMX resulted in a prompt increase in conductance, which reached a steady state 
after 20-30 minutes.   The addition of inhibitors to the perfusate consequently 
caused a decrease in conductance.   The dose response of the CFTR mediated 
conductance is observed as a stepwise decrease in conductance as increasing 
concentrations of the specific inhibitors are added to the perfusate.  In contrast to 
the similarities observed across species of CFTR after stimulation by forskolin 
and IBMX, the response to each inhibitor was different across species.  
 The I-V relationships for the oocytes are demonstrated in Figures 5b and 6b.  
Throughout all experiments, all species of CFTR injected oocytes exhibited 
similar linear I-V relationships.  After the addition of forskolin and IBMX, the 
reversal potentials depolarized toward the resting potential of chloride.   
Similarly, after the addition of the various inhibitors that caused inhibition of 
CFTR mediated anion conductance, the reversal potential re-polarized toward 
basal values.  
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sCFTR by CFTRinh-172 is highly significant (P=0.001 for 5µM, P=1.5*10-5for 
10µM and P=2*10-7 for 20µM) when compared to hCFTR. (Figure 5a)  
I-V plots for both species are shown in Figure 5b and demonstrate similar 
currents between between human and sCFTR at basal and stimulated conditions and 
different responses in current after addition of CFTRinh-172 to the perfusate.  I-V 
ramps were taken at the end of each of the following conditions: baseline perfusion 
with frog ringer solution until the 
conductance reached a baseline steady 
state, stimulation with forskolin (10µM) 
and IBMX (1mM) until conductance 
reached a new steady state and inhibition 
with CFTRinh-172 (20µM).  
 To further explore the findings that sCFTR is unresponsive to CFTRinh-
172, in vitro inhibition was examined using both isolated shark rectal glands in 
perfusion studies and by measurement of short circuit current (Isc) in primary 
culture monolayers of rectal gland tubular cells.  Perfusion studies confirmed that 
Figure 5: Comparison of the effects of CFTRin-172 on 
CFTR species. 
B: Representative I-V plots from oocytes expressing h- 
and sCFTR.  Human- and sCFTR show similar currents 
at baseline and after stimulation. However, they differ 
significantly in the currents they exhibit after inhibition 
with CFTRinhib172. 
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CFTRinh–172 had no effect on chloride secretion in the shark rectal gland (Figure 
6). The effects of CFTRinh–172 on chloride secretion in rectal gland monolayer cells 
were consistent with the perfusion studies.  Addition of 1, 5 and 10 µM CFTRinh–
172 to 1 µM forskolin and 100 µM IBMX stimulated cells showed no inhibition in 
four experiments (results not shown).  
 
 
 
 
 
Glibenclamide:  pCFTR is unresponsive to Glibenclamide  
Similar to the experiments with CFTRinh-172, we compared the dose 
response of the four different CFTR species to glibenclamide (5, 10 and 20µM).  
Glibenclamide inhibited hCFTR significantly (29.7 ± 3.7% inhibition at 5µM, 44.6 
± 1.9% at 10 µM and 61.3 ± 3.7% at 20µM). Unlike CFTRinh-172, sCFTR was 
Figure 6: Chloride secretion in perfused shark rectal glands with 1 µM forskolin and 100 µM IBMX added 
to the perfusate. CFTRinh–172 (10 µM) was added from 50-70 min in experimental studies (n=5) and 
effects were compared to controls (n=18).  Values are mean  SEM. Forskolin and IBMX are squares,  
CFTRinh-172 are diamonds. 
Time (min)
0
500
1000
1500
2000
2500
3000
3500
0 10 20 30 40 50 60 70 80 90
CFTR-172 (10M)
Forskolin (1M) + IBMX (100M)
C
hl
or
id
e 
S
ec
re
tio
n 
(µ
E
q/
h/
g)
 
Forskolin +IBMX 
C
  27
responsive to glibenclamide (30.2 ± 4.5% inhibition at 5µM, 40 ± 8.6% at 10 µM 
and 52.2 ± 7.7% at 20µM) (Figure 7a). Similar to CFTRinh-172, kfCFTR was also 
less. 
 Interestingly, pCFTR was highly significantly unresponsive to 
glibenclamide (4.9 ± 1.7% inhibition at 5µM, 10.2 ± 4.2% at 10 µM and 12.8 ± 
4.2% at 20µM, P < 0.001 in all concentrations) in comparison to human. 
 I-V plots for both species are shown in Figure 7b and demonstrate 
similar currents between human and pCFTR at basal and stimulated conditions and 
different responses in current after addition of glibenclamide to the perfusate.    
Figure 7: Comparison of the effects of Gibenclamide on CFTR species. 
A: Summary of % Inhibition of h-, kf-, p- and sCFTR with 50, 100 and 200 µM of Glibenclamide. 
Importantly, % inhibition of pCFTR by Glibenclamide (4.9 ± 1.7% inhibition at 5µM, 10.2 ± 4.2% at 10 
µM and 12.8 ± 4.2% at 20µM) was  highly significant at all concentrations studied (p<0.001) when 
compared to human. 
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These results are supported by recently reported observations in short circuit 
current studies with human, pig, ferret and mouse that pCFTR is less sensitive than 
hCFTR to glibenclamide (48).  
 
 
 
GlyH-101: All species are responsive to GlyH-101  
  In contrast to CFTRinh-172 and glibenclamide, hCFTR, kfCFTR, 
sCFTR and pCFTR are all responsive to GlyH-101. This inhibition is particularly 
evident at the highest concentration used (20µM).  Shark, kfCFTR and pCFTR are 
inhibited more by GlyH-101 than hCFTR (hCFTR: 47.8 ± 4.7%; kfCFTR: 58.1 ± 
Figure 7:  Comparison of the effects of 
Glibenclamide on different CFTR 
species.  
B: Representative I-V plots from 
oocytes expressing h-  and pCFTR.  
Human- and pCFTR show similar 
currents at baseline and after 
stimulation. However, they differ 
significantly in the currents they exhibit 
after inhibition with Glibenclamide. 
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agents that are known to interact with and block the ion channel. (58) These small 
molecule pore blocking agents are used as probes of the ion pore to analyze the 
effects of mutagenesis on blocking behavior.  The term “reverse pharmacology” 
was coined because the known structure of the inhibitor was used to investigate the 
unknown contours of the channel pore. (32, 53) Our study design uses this concept 
of reverse pharmacology to analyze the behavior of known inhibitors on several 
species of CFTR rather than in mutagenesis studies.  The benefit of using cross 
species analysis is that we avoid the limitations of mutagenesis studies, wherein 
single amino acid changes disrupt channel function through global changes in the 
secondary or tertiary structure of the protein. 
We studied the effects of three inhibitors on four isoforms of CFTR, each 
with varying sequence identity to the human isoform and each with distinct 
sequence motifs. The pharmacologic profiles of each CFTR isoform would be 
expected to elucidate structure and functional relationships. 
Charged Vestibule Model of CFTR 
 The “charged vestibule model”, described by Green and Andersen in 1991, 
proposed that the general features of channel structure are the result of evolutionary 
pressure due to the limitations on the rate of ion conduction imposed by diffusion. 
(16) They reviewed theoretical and experimental data, which suggested that the 
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rapid ion translocation across the thickness of a biological membrane could only be 
possible if the narrow region of the pore responsible for selectivity and binding, is 
flanked by vestibules designed to increase the capture radius at the channel mouth, 
and to concentrate permeable ions by electrostatic means. (21) This model is widely 
used in the literature (17, 54) to explain structure-function relationships of CFTR. 
 
  
 
 
 
 
 
The charged vestibule model proposes that the CFTR channel pore consists 
of three regions: an outer vestibule, pointing towards the outside of the cell 
Figure 9: The charged vestibule model of CFTR mediated chloride transport.  Site directed 
mutagenesis studies have implicated several positively charged amino acids in the vestibules and 
pore in the attraction and binding of chloride. (17, 21, 22, 28, 55-56) Experimental studies suggest 
that GlyH-101 occludes the pore extra-cellularly and that glibenclamide occludes chloride transport 
intra-cellularly. (31, 40)  CFTRinh-172 may act on the R domain to inhibit chloride conductance. 
(36-39) 
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membrane, a narrow region, which is the rate limiting area of the selectivity filter 
and an inner vestibule, that is opened towards the cytoplasm. (Figure 9) 
Because CFTR is predominantly permeant to negatively charged chloride 
ions, positive charges within the pore are theorized to promote the accumulation of 
chloride and to create a conditioned environment adjacent to the rate-limiting 
narrow section of the pore. Several site-specific mutagenesis experiments have 
observed changes in conductance and current-voltage rectification secondary to 
mutations made within the CFTR pore.  These observations suggested that 
positively single charged residues are an essential part of the outer and inner 
vestibules.  Several permeant anion binding sites exist. The positive charges in the 
outer vestibule are R334 and K335 in TM6 and R104 and R117 in extracellular 
loop 1 and the positive charges in the inner vestibule are K95 and R303 in TM1 and 
TM5. (17, 28, 55-56) These amino acids are considered important in drawing 
extracellular and intracellular chloride anions respectively into the central narrow 
pore region. The residues R347 and R352, both present in TM6 are a part of the R 
domain but are theorized to be important in permeation, open state stability and 
structural integrity.  The residues, F337, T338 and S341 are present in the narrow 
region of the pore and may play role in the rate limiting steps of anion permeation. 
(21-22) As CFTR specific inhibitors GlyH101 and Glibenclamide are both 
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negatively charged and the CFTRinh-172 is at least hydrophobic, these positively 
charged amino acids important in chloride anion attraction and binding may also be 
important binding sites for inhibition by small molecules. (40, 35) The negatively 
charged inhibitors may therefore be competing with chloride anions for affinity and 
binding within the CFTR pore providing a mechanism for occlusion and inhibition. 
(Figure 10 ) 
CFTRinh-172: sCFTR and residues 347 and R352 
 We demonstrated in three experimental models, including, (1) two electrode 
voltage clamping (TEVC) of Xenopus laevis oocytes, (2) short circuit current 
studies in shark rectal gland tissue monolayers from primary tissue culture and (3) 
intact shark rectal gland perfusions that sCFTR shows nearly no response to 
CFTRinh-172.  TEVC studies further demonstrated that pig and kfCFTR are 
significantly less responsive to CFTRinh-172 than hCFTR.  Recent work provides 
evidence that CFTRinh-172 interacts directly with CFTR’s R domain at a region 
that is important to formation of the channel.  (37) Mutations introduced at R347 
and R352 in TM6, replaced arginine with alanine, and demonstrated decreased 
inhibitory potency in functional assays. (37)  
 Because of the observation that CFTRinh-172 has decreased potency of 
inhibition in functional studies with pig and kfCFTR and almost no potency with 
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sCFTR, we proposed that the amino acids identities at position 347 and 352 were 
substituted with different amino acids, perhaps not neutral or less positively charged 
than arginine.  However, examination of the sequence alignment of these four 
CFTR isoforms reveals positions R347 and R352 have perfect consensus. (Figure 
10)  This sequence conservation suggests that these two residues alone are not 
sufficient to explain the mechanism of action of CFTRinh-172.  Looking closer at 
the amino acid sequence adjacent to R347 and 352, positions 349 and 356 and 357, 
were less conserved across species.  In human and pig, the non-polar amino acid, 
alanine, are present at positions 349 and 357 and the polar residue tryptophan is 
present at position 357.  In shark and killifish, these non-polar and polar residues 
are replaced with threonine and serine respectively, both with partial negative 
charges.  These partial negative charges may decrease the potency of CFTRinh-172 
by decreasing the affinity of the polar organic compound to the adjacent positively 
charged arginine residues.   However, this does not explain the observed decreased 
potency of the inhibitor on pCFTR as the residues in this region are completely 
conserved with its human isoform. 
Glibenclamide: pCFTR and residues K95 and R303 
The most striking difference in pharmacologic profiles demonstrated by 
TEVC studies was that pCFTR mediated chloride conductance was completely 
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unresponsive to glibenclamide and that kfCFTR showed decreased response when 
compared to shark and hCFTR.  This observation confirmed previously published 
short circuit current studies that pig was unresponsive to inhibition by 
glibenclamide. (48) Glibenclamide is thought to block the CFTR channel in a 
complex mechanism by interacting with multiple binding sites with varying degrees 
of affinity that is both voltage and pH dependent.  Patch clamp studies suggest that 
glibenclamide blocks CFTR by interacting with two sites within the channel pore 
and one site that lies in the inner vestibule. (32) The amino acids K95 and R303 
have been proposed to be important with glibenclamide’s interaction with the inner 
vestibule. (34, 56)  Therefore, we hypothesized that there may exist a species-
specific difference in the amino acid sequence at K95 and R303 that accounts for 
the differences in pharamacologic profiles observed in our TEVC studies.  
However, examination of the amino acid sequence alignment of the four isoforms 
demonstrates conservation of these residues suggesting that these residues are not 
solely responsible for the interactions of glibenclamide with the channel pore.  We 
again examined the amino acid sequence alignment adjacent to K95 and R303.  In 
human and sCFTR the non-polar residues alanine and leucine occupy position 96 
and 102.  These positions in the killifish isoform are occupied by threonine and 
serine respectively, which have partial negative charges.   This could, again, 
theoretically explain the differences in inhibitory profile observed with kfCFTR.  
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However, the residues K95 and R303 are conserved in pCFTR.  The absent 
inhibition of pCFTR mediated conductance may be due to differences in sequence 
homology between the CFTR isoforms at the two other suggested sites that 
glibenclamide is theorized to interact with in the channel pore.  
GlyH101: Residues R334, K335, R104 and R117 
 All four CFTR isoforms were rapidly and significantly responsive to GlyH-
101 mediated inhibition of chloride conductance.  Furthermore, shark and pCFTR 
were comparatively more responsive to GlyH-101 inhibition than human and 
kfCFTR, which is in contrast to shark and pCFTRs relative decreased sensitivity to 
CFTRinh-172 and glibenclamide.   GlyH-101 is like glibenclamide, an open 
channel blocker, but GlyH-101 is unique because it acts by a novel external pore 
occluding mechanism.  Compared with both CFTRinh-172 and glibenclamide, 
GlyH-101 is >50 fold more water-soluble and is rapid and reversible suggesting it 
acts at the extracellular face of the channel.  The positively charged residues R334, 
K335, R104 and R117 have been proposed to be essential to GlyH-101’s interaction 
with the outer vestibule. (28, 40, 57)   These four residues are conserved in all four 
species of CFTR studied.  As all four isoforms of CFTR are sensitive to GlyH-101 
inhibition, the conservation of these four residues may confirm their importance in 
GlyH-101 function.    Examination of the amino acid sequences adjacent to the 
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positively charged arginine and lysine residues reveals that at position 115 in 
hCFTR, a strongly negatively charged glutamic acid residue resides, where as in 
shark and pig CFTR, position 115 is occupied by the neutral residue alanine.  Shark 
CFTR furthermore has a positively charged residue at position 113 which is not 
present in the other isoforms.  Shark CFTR demonstrated rapid inhibition by GlyH-
101 even at the smallest concentrations studied.   The replacement of a negatively 
charged residue with a neutral residue, and the addition of a positively charged 
residue, at region thought to be important for the attraction and binding of the 
negatively charged GlyH-101 may explain the potency of this particular inhibitor 
when interacting with shark CFTR.  
Figure 10: Amino Acid Sequence Alignment of Human, Pig, Shark and Killifish CFTR: Conserved residues that are suggested 
to be important for CFTR specific inhibitor binding are in bold. Green amino acids are proposed binding sites for CFTRinh 
172, red are for glybenclamide, and yellow for glyH-101. The sequence alignment was made using ClustalW2 Alignment and 
Biological Workbench. Key: “*” means that the residues in the column are identical in all sequences in the alignment. “:” 
means that conserved substitutions have been observed. “.” means that semi-conserved substitutions are observed. 
Human           MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRE 60 
Killifish       MQKSPVEDANFLSRFVFWWITPLLRKGFTKKLELTDVYKAPSFDLADTLSERLEREWDKE 60 
Pig             MQRSPLEKASIFSKLFFSWTRPILRKGYRQRLELSDIYHISSSDSADNLSEKLEREWDRE 60 
Shark           MQRSPIEKANAFSKLFFRWPRPILKKGYRQKLELSDIYQIPSSDSADELSEMLEREWDRE 60 
                **:**:*.*. .*::.* *  *:*:**: ::***:*:*: .* * ** *** ******:* 
 
Human           LAS-KKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSI 119 
Killifish       VVLAKGRPKLLKALARCFFLPFAFFGVLLYLGEASKTVQPQLSGRIIASFDPFHAAERSQ 120 
Pig             LAS-KKNPKLINALRRCFFWRFMFYGIILYLGEVTKAVQPLLLGRIIASYDPDNKAERSI 119 
Shark           LATSKKNPKLVNALRRCFFWRFLFYGILLYFVEFTKAVQPLCLGRIIASYNAKNTYEREI 120 
                :.  * .***::** ****  * *:*::**: * :*:***   ******::. :  **.  
 
Human           AIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQ 179 
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Killifish       GYYLALGLGLLFTARFILLQPAIYGLHHLGMQIRIALFSLIYKKTLKLSSKVLDKISTGQ 180 
Pig             AIYLGVGLCLLFIVRTLLLHPAIFGPHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQ 179 
Shark           AYYLALGLCLLFVVRTLFLHPAVFGLQHLGMQMRIALFSLIYKKILKMSSRVLDKIDTGQ 180 
                . **.:** *** .* ::*:**::* :*:***:***:******* **:**:*****. ** 
 
Human           LVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAG 239 
Killifish       LVSLMSAHLNKLDESLGLAHFVWITPLQCILCTGLIWELIEVNGFCALASLTLLGILQAW 240 
Pig             LVSLLSNNLNKFDEGLALAHFVWIAPLQVTLLMGLLWELLQASAFCGLAFLVVLALFQAG 239 
Shark           LVSLLSNNLNKFDEGVAVAHFVWIAPVQVVLLMGLIWNELTEFVFCGLGFLIMLALFQAW 240 
                ****:* :***:**.:.:******:*:*  *  **:*: :    **.*. * :*.::**  
 
Human           LGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKA 299 
Killifish       LSLKMGPPRAQRAGLINRRLALTSEIVENIHSVKAYGWEEVMETIIKNIRQDEMTLTRKI 300 
Pig             LGKMMMKYRDQRAGKINERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKA 299 
Shark           LGKKMMQYRDKRAGKINERLAITSEIIDNIQSVKVYCWEDAMEKIIDDIRQVELKLTRKV 300 
                *.  *   * :*** *..**.:***:::**:***.* **:.**.:*.::** *:.****  
 
Human           AYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQ 359 
Killifish       GSLRYFYSASYFFSAILVIVSAIVPHALSNGIILRRIFTTASYCVVLRMTLTRQLPGSIQ 360 
Pig             AYVRYFNSSAFFFSGLFVVFLSVLPYALLKGIMLRKIFTTISFCIVLRMAVTRQFPWAVQ 359 
Shark           AYCRYFSSSAFFFSGFFVVFLSVVPYAFIHTIKLRRIFTTISYNIVLRMTVTRQFPSAIQ 360 
                .  *** *:::***.::*:. :::*:*: : * **:**** *: :****::***:* ::* 
 
Modulation of Channel Gating 
The unique interactions observed between the GlyH-101, CFTRinh-172 and 
glibenclamide and different species of CFTR despite amino acid sequence 
conservation in the charged vestibule and regulatory domains may also be explained 
by the complex nature of species specific channel kinetics and by the binding 
affinity or equilibrium dissociation constant of each inhibitor.  The macroscopic 
conductance Gj for ion j is given by: 
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Gj  = gj x N x Po 
where is gj the individual conductance of each channel, N is the number of available 
channels in a given membrane and Po is open probability of that  channel.  In our 
studies, we assumed that the number of available channels measured during each 
experiment did not affect the percent inhibition of maximal stimulation. We 
furthermore, assumed that channel conductance, gj, did not differ between species 
of CFTR and that the open probability of each channel were similar and that small 
differences did not contribute to the macroscopic conductance measured. However, 
identical Gj  = gj x N x Po, do not necessarily imply identical gj, N or Po: for 
example a small number of channels with a greater open probability may be equal 
to a large number of channels with a low open probability.  Several recent studies 
have revealed single channel conductance differences between xenopus laevis, 
human and shark CFTR: xenopus laevis CFTR demonstrates significantly greater gj 
than the human and shark isoforms.  Furthermore single channel conductance 
studies demonstrate differences between the open probabilities of CFTR isoforms.  
A notably reduced Po of mouse CFTR was observed when compared with rodent 
(59, 60) and human CFTR (61).  The gating behavior of mouse CFTR has also been 
observed to be dramatically different than human CFTR with differing patterns of 
channel openings and closures. (61, 62) Glibenclamide, GlyH-101 and CFTRinh-
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172 are all open channel inhibitors (63, 40, 64) that act by presumably shortening 
the open time but not the closed time of the channel.  The rate of association and 
disassociation of these inhibitors with their binding sites may be influenced by the 
kinetics of opening and closing of each channel.  Therefore, the individual channel 
kinetic characteristics and the binding affinities of each inhibitor may influence the 
macroscopic differences in conduction and inhibition observed. 
Conclusion:  Questioning the Single Amino Acid Binding Models. 
In summary, we demonstrate in this study and confirm previously reported 
observations (41, 40, 48) that cross species examination of the CFTR protein 
reveals unique pharmacologic profiles for several CFTR specific inhibitors. These 
distinct species differences cannot be explained by reverse pharmacology because 
the proposed amino acids that these inhibitors interact with are uniformly conserved 
across the species studied and thus cannot account for the differences in function 
observed.  This study suggests that the binding of the inhibitors with the channel 
vestibule and pore is likely the result of a complex interaction involving multiple 
amino acids at multiple sites.  Ion transport is dependent on the unique matrix of 
charged residues in the vestibules and pore, which create electrostatic potentials that 
increase conductance by increasing the concentration of chloride.  In this complex 
picture of selectivity, the positioning of positively or partially charged residues is 
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vital to channel function.  
Therefore, the differences in inhibition demonstrated across diverse CFTR 
species cannot be explained by simply targeting one amino acid for site-directed 
mutagenesis.  Rather, the potency of inhibitory actions of CFTRinh-172, GlyH-101 
and gibenclamide on the CFTR molecule is dictated by the local environment and 
the three dimensional structure of residues that form the vestibule and the chloride 
pore and regulatory domain.  The identity of the amino acids that play important 
roles in binding and inhibition may not fully be understood until the crystal 
structure of the CFTR protein is solved. 
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